^
    Back
    Association details:
    Biomarker:PD-L1 overexpression
    Cancer:Lung Non-Small Cell Squamous Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    02/16/2021
    Excerpt:
    PD-L1 expression positive (≥50%)…squamous cell carcinoma…Preferred…Pembrolizumab (category 1)
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    02/16/2021
    Excerpt:
    PD-L1 expression positive (≥50%)…squamous cell carcinoma…Preferred…Carboplatin + (paclitaxel or albumin-bound paclitaxel) + Pembrolizumab (category 1)
    Secondary therapy:
    carboplatin + albumin-bound paclitaxel; carboplatin + bisphosphonate bound paclitaxel
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Immunol Immunother
    Title:

    First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 >= 50%: a systematic review and network meta-analysis

    Published date:
    10/16/2021
    Excerpt:
    ...we aimed to evaluate the efficacy and toxicity of first-line single-agent ICIs versus ICI combinations for advanced NSCLC patients with PD-L1 ≥ 50%....The results showed that chemotherapy plus ICIs significantly improved PFS and ORR compared to chemotherapy, and sinti-chemo (HR: 0.31, 95% CI: 0.20-0.49) and pembro-chemo (OR: 4.2, 95% CI: 2.6-6.7) ranked first....In the subgroup analysis of histological type, pembro-chemo and sinti-chemo showed the best benefit of PFS in squamous and nonsquamous NSCLC, respectively...
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1007/s00262-021-03089-x